Breaking News, Collaborations & Alliances

ReciBioPharm, Acuitas Partner on cGMP Mfg. of LNP Formulations

Will perform technology transfers and manufacturing for customers licensing Acuitas’ lipid nanoparticle formulations.

ReciBioPharm and Acuitas Therapeutics will perform technology transfers and current good manufacturing practice (CGMP) manufacturing for customers licensing Acuitas’ lipid nanoparticle (LNP) formulations for mRNA-based therapeutics and vaccines. ReciBioPharm first partnered with Acuitas Therapeutics in May of 2022 as Arranta Bio (now part of ReciBioPharm) and has since transferred and manufactured multiple Acuitas LNP formulations for planned clinical trials around the globe. Ongoing work ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters